

## **IB. CLAIMS**

Please amend the claims as follows:

Claim 1. (**Currently Amended**): An isolated human antibody that specifically binds to botulinum neurotoxin type A (BoNT/A), wherein said antibody comprises a heavy variable domain (VH) comprising complementarity determining regions having the amino acid sequence of VH CDR1 (SEQ ID NO: **[[87]] 139**), VH CDR2 (SEQ ID NO: **[[89]] 141**), and VH CDR3 (SEQ ID NO: **[[127]] 179**).

Claims 2-16 (Canceled).

Claim 17 (**Currently Amended**): An isolated human antibody that specifically binds to botulinum neurotoxin type A (BoNT/A), wherein said antibody comprises a light variable domain (VL) comprising complementarity determining regions having the amino acid sequence of VL CDR1 (SEQ ID NO: **[[157]] 209**), VL CDR2 (SEQ ID NO: **[[159]] 211**), and VL CDR3 (SEQ ID NO: **[[197]] 249**).

Claim 18 (**Currently Amended**): An isolated human antibody that specifically binds to botulinum neurotoxin type A (BoNT/A), wherein said antibody further comprises a heavy variable domain (VH) comprising complementarity determining regions having the amino acid sequence of VH CDR1 (SEQ ID NO: **[[87]] 139**), VH CDR2 (SEQ ID NO: **[[89]] 141**), and VH CDR3 (SEQ ID NO: **[[127]] 179**); and a light variable domain (VL) comprising complementarity determining regions having the amino acid sequence of VL CDR1 (SEQ ID NO: **[[157]] 209**), VL CDR2 (SEQ ID NO: **[[159]] 211**), and VL CDR3 (SEQ ID NO: **[[197]] 249**).

Claims 19-22 (Canceled).

Claim 23 (Previously Presented): The antibody of any one of claims 1, 17, or 18, wherein said antibody is a single chain Fv (scFv).

Claim 24 (Previously Presented): The antibody of any one of claims 1, 17, or 18, wherein said antibody is an IgG.

Claim 25 (Previously Presented): The antibody of any one of claims 1, 17, or 18, wherein said antibody is a Fab.

Claim 26 (Previously Presented): The antibody of any one of claims 1, 17, or 18, wherein said antibody is a (Fab')<sub>2</sub>.

Claim 27 (Previously Presented): The antibody of any one of claims 1, 17, or 18, wherein said antibody is a (scFv')<sub>2</sub>.

Claim 28 (Original): The antibody of claim 27, wherein said antibody is a fusion protein of two scFv fragments.

Claim 29 (Previously Presented): The antibody of claim 1, wherein said antibody comprises the heavy variable framework region of huC25.

Claim 30 (Previously Presented): The antibody of claim 17, wherein said antibody comprises the light variable framework region of huC25.

Claim 31 (Previously Presented): The antibody of claim 1, wherein said antibody comprises a variable heavy region of huC25.

Claim 32 (Previously Presented): The antibody of claim 17, wherein said antibody comprises the variable light region of huC25.

Claim 33 (Previously Presented): The antibody of claim 18, wherein said antibody comprises the variable heavy region of huC25 and the variable light region of huC25.

Claims 34 (Previously Presented): The antibody of claim 18, wherein said antibody comprises the amino acid sequence of huC25 scFv.

Claims 35-115 (Canceled).

Claim 116 (Previously Presented): A composition comprising a plurality of anti-botulinum neurotoxin antibodies, wherein each species of antibody is specific for a different epitope of a botulinum neurotoxin, and wherein said combination of antibodies shows greater toxin neutralization than the single antibodies comprising said plurality, and wherein said composition comprises an antibody according to any one of claims 1, 17, or 18.

Claim 117 (Original): The composition of claim 116, wherein said composition comprises a first antibody that binds and neutralizes an A1 toxin and a second antibody that binds and neutralizes an A2 toxin.

Claim 118 (Canceled).